Sign In
Buy IOVA
$4.44
+0.380 (+9.36%)
At Close: Jun 23, 2026
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
07:33pm, Tuesday, 23'rd Jun 2026
Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for ad
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 19'th Jun 2026
SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deli
Iovance Biotherapeutics: Commercial, Clinical And Regulatory Tailwinds
11:31am, Wednesday, 17'th Jun 2026
IOVA guides for $350M–$370M 2026 revenue (36% YoY growth), with Q2'26 expected to be a record Amtagvi quarter. Expansion into new indications (NSCLC, endometrial, sarcoma) and global markets underpi
Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
04:05pm, Wednesday, 03'rd Jun 2026
First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?
12:15am, Tuesday, 02'nd Jun 2026
Iovance Biotherapeutics has surged over the past year, but the stock is down by nearly 80% over the past five years. Past issues with dilution and disappointment may be clearing up, given recent sales
Iovance Biotherapeutics pushes cell therapy platform into solid tumor market
12:32pm, Monday, 01'st Jun 2026
Iovance Biotherapeutics (NASDAQ:IOVA) said it has obtained clearance of an Investigational New Drug application for IOV-5001, extending its next-generation cell therapy platform into solid tumors the
Iovance Biotherapeutics pushes cell therapy platform into solid tumor market
08:29am, Monday, 01'st Jun 2026
Iovance Biotherapeutics (NASDAQ:IOVA) said it has obtained clearance of an Investigational New Drug application for IOV-5001, extending its next-generation...
Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a co
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?
11:50am, Thursday, 28'th May 2026
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 22'nd May 2026
SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliv
Iovance Biotherapeutics to Present at Upcoming Conference
08:05am, Thursday, 21'st May 2026
SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infi
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
12:11pm, Friday, 08'th May 2026
Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity
10:58am, Friday, 08'th May 2026
Iovance Biotherapeutics, Inc. markets Amtagvi, a TIL therapy for advanced melanoma, and just reported Q1 earnings. Following Q1 results, IOVA shares declined over 13%, closing at $3.55, with a market
Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript
05:21pm, Thursday, 07'th May 2026
Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates
09:56am, Thursday, 07'th May 2026
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.19 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.
